RGNX Seeks FDA Approval
REGENXBIO plans to resubmit its one-time gene therapy for Hunter Syndrome to the FDA after a path forward was established.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.